https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-02-23 / Int. J. Oncol. 2018 Apr;52(4):1041-1056
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-02-23 / Int. J. Oncol. 2018 Apr;52(4):1041-10562018-02-23 00:00:002019-02-15 08:32:54Importance of immune monitoring approaches and the use of immune checkpoints for the treatment of diffuse intrinsic pontine glioma: From bench to clinic and vice versa (Review)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-02-22 / Sci Rep 2018 Feb;8(1):3474
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-02-22 / Sci Rep 2018 Feb;8(1):34742018-02-22 00:00:002018-02-22 00:00:00Non-Invasive Radiofrequency Field Treatment of 4T1 Breast Tumors Induces T-cell Dependent Inflammatory Response
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-02-21 / Hum Vaccin Immunother 2018 Jun;14(6):1423-1431
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-02-21 / Hum Vaccin Immunother 2018 Jun;14(6):1423-14312018-02-21 00:00:002018-02-21 00:00:00Inhibition of IL-10 and TGF-β receptors on dendritic cells enhances activation of effector T-cells to kill cholangiocarcinoma cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-02-15 / Blood Rev. 2018 Jul;32(4):312-325
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-02-15 / Blood Rev. 2018 Jul;32(4):312-3252018-02-15 00:00:002019-02-15 08:32:43Anti-cancer vaccine therapy for hematologic malignancies: An evolving era
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-02-13 / Nat Rev Urol 2018 Apr;15(4):235-250
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-02-13 / Nat Rev Urol 2018 Apr;15(4):235-2502018-02-13 00:00:002018-02-13 00:00:00Potentiating prostate cancer immunotherapy with oncolytic viruses
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-02-08 / JCI Insight 2018 Feb;3(3)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-02-08 / JCI Insight 2018 Feb;3(3)2018-02-08 00:00:002019-02-15 08:32:51Efficacy of intracellular immune checkpoint-silenced DC vaccine
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-02-08 / Int. J. Biol. Macromol. 2018 Jul;113:1182-1187
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-02-08 / Int. J. Biol. Macromol. 2018 Jul;113:1182-11872018-02-08 00:00:002019-02-15 08:35:40Poly(I:C) enhanced anti-cervical cancer immunities induced by dendritic cells-derived exosomes
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-02-08 / J Clin Oncol 36, 2018 (suppl 6S; abstr 219)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-02-08 / J Clin Oncol 36, 2018 (suppl 6S; abstr 219)2018-02-08 00:00:002018-02-08 00:00:00Myeloid and plasmacytoid dendritic cell vaccinations for castration-resistant prostate cancer patients.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-02-01 / Trends Cancer 2018 02;4(2):119-137
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-02-01 / Trends Cancer 2018 02;4(2):119-1372018-02-01 00:00:002019-02-15 08:45:24Re-Emergence of Dendritic Cell Vaccines for Cancer Treatment
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-01-31 / Mol. Ther. 2018 04;26(4):1008-1019
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-01-31 / Mol. Ther. 2018 04;26(4):1008-10192018-01-31 00:00:002019-02-15 09:23:16Pre-existing Immunity to Oncolytic Virus Potentiates Its Immunotherapeutic Efficacy
